Zymeworks (NASDAQ:ZYME) Stock Rating Lowered by Wall Street Zen

Zymeworks (NASDAQ:ZYME) was downgraded by research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Sunday.

A number of other analysts have also issued reports on the company. HC Wainwright raised Zymeworks from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a report on Wednesday, October 8th. Finally, B. Riley raised Zymeworks to a “strong-buy” rating in a report on Thursday, October 9th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

Zymeworks Stock Performance

Shares of NASDAQ ZYME opened at $18.40 on Friday. Zymeworks has a 12 month low of $9.03 and a 12 month high of $19.50. The stock has a market capitalization of $1.38 billion, a P/E ratio of -18.97 and a beta of 1.51. The company’s fifty day moving average is $15.76.

Zymeworks (NASDAQ:ZYME) last announced its earnings results on Tuesday, November 8th. The company reported ($1.14) EPS for the quarter. The company had revenue of $4.40 million for the quarter. Zymeworks had a negative net margin of 59.96% and a negative return on equity of 21.59%.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.